Literature DB >> 27388234

Cardiogenic Shock and Respiratory Failure in a Patient With Metastatic Melanoma Receiving Trametinib Therapy.

Diane Tseng1, Xenos L Mason2, Tomas G Neilan3, Ryan J Sullivan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27388234      PMCID： PMC5016073          DOI： 10.1634/theoncologist.2016-0080

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.

Authors:  Peter D Boasberg; Charles H Redfern; Gregory A Daniels; David Bodkin; Chris R Garrett; Alejandro D Ricart
Journal:  Cancer Chemother Pharmacol       Date:  2011-04-24       Impact factor: 3.333

3.  Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.

Authors:  Xi Chen; Gary K Schwartz; Lisa M DeAngelis; Thomas Kaley; Richard D Carvajal
Journal:  Neurology       Date:  2012-10-17       Impact factor: 9.910

4.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Authors:  Jeffrey R Infante; Leslie A Fecher; Gerald S Falchook; Sujatha Nallapareddy; Michael S Gordon; Carlos Becerra; Douglas J DeMarini; Donna S Cox; Yanmei Xu; Shannon R Morris; Vijay G R Peddareddigari; Ngocdiep T Le; Lowell Hart; Johanna C Bendell; Gail Eckhardt; Razelle Kurzrock; Keith Flaherty; Howard A Burris; Wells A Messersmith
Journal:  Lancet Oncol       Date:  2012-07-16       Impact factor: 41.316

5.  Inhibition of extracellular signal-regulated kinase enhances Ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in isolated perfused heart.

Authors:  T L Yue; C Wang; J L Gu; X L Ma; S Kumar; J C Lee; G Z Feuerstein; H Thomas; B Maleeff; E H Ohlstein
Journal:  Circ Res       Date:  2000-03-31       Impact factor: 17.367

6.  Respiratory syncytial virus and heart disease. A report of two cases.

Authors:  T D Giles; R S Gohd
Journal:  JAMA       Date:  1976-09-06       Impact factor: 56.272

7.  Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults.

Authors:  Neil E Bowles; Jiyuan Ni; Debra L Kearney; Matthias Pauschinger; Heinz-Peter Schultheiss; Robert McCarthy; Joshua Hare; J Timothy Bricker; Karla R Bowles; Jeffrey A Towbin
Journal:  J Am Coll Cardiol       Date:  2003-08-06       Impact factor: 24.094

8.  Stimulation of the p38 mitogen-activated protein kinase pathway in neonatal rat ventricular myocytes by the G protein-coupled receptor agonists, endothelin-1 and phenylephrine: a role in cardiac myocyte hypertrophy?

Authors:  A Clerk; A Michael; P H Sugden
Journal:  J Cell Biol       Date:  1998-07-27       Impact factor: 10.539
  8 in total
  2 in total

1.  Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.

Authors:  Arthur E Frankel; Ugur Eskiocak; Jennifer G Gill; Stacy Yuan; Vijayashree Ramesh; Thomas W Froehlich; Chul Ahn; Sean J Morrison
Journal:  Neoplasia       Date:  2017-03-06       Impact factor: 5.715

Review 2.  Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism.

Authors:  Mary Banks; Karen Crowell; Amber Proctor; Brian C Jensen
Journal:  Cardiovasc Toxicol       Date:  2017-10       Impact factor: 3.231
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.